|


 

 
 
Jeremy Moore, M.A.
Senior Manager, Science Communications
American Association for Cancer Research
jeremy.moore@aacr.org
Why
 hy?
 Why
 hy?

° umber 1 cause of death, surpassing heart

disease in 2010
 Why
 hy?

° umber 1 cause of death, surpassing heart

disease in 2010
°
n the United States, it affects one in three
women and one in two men
 Why
 hy?

° umber 1 cause of death, surpassing heart

disease in 2010
°
n the United States, it affects one in three
women and one in two men
° Consequences both biological and psychological
 Why
 hy?

° Money
 Why
 hy?

° Money
° overnment Money
ƛ C
Budget, 2009: $4.96 billion
ƛ C
Budget, 2010: $5.1 billion
 Why
 hy?

° Money
° overnment Money
ƛ C
Budget, 2009: $4.96 billion
ƛ C
Budget, 2010: $5.1 billion

Budget Request for 2011

$5.26 Billion
 Why
 hy?

° Money
° rivate Money
 Why
 hy?
° Money
° rivate Money
° Corporate and hilanthropic

 
 y

Ö
n fact
have not failed 1,000 times.

have successfully discovered 1,000
ways not to make a light bulb.ơ
--Thomas Edison

 
 y

° Cancer

 
 y

° Cancer
° ut of control cell growth

 
 y

° Cancer
° ut of control cell growth
° More than 200 diseases
 


CURE?
 


CURE
vs.
C TR
 
h 
 
 

° iagnosis
 V

° Bladder Cancer ° Breast Cancer

° ancreatic Cancer ° Colon Cancer
° varian Cancer ° Skin Cancer
 
h 
 
 

° iagnosis
° Screening

 

° uestions surrounding SA, Mammography,

Colonoscopy
 y


y

y


y
° Correctly
dentifying Who ° Correctly
dentifying Who

s Sick
s ot Sick
 —
|

ÖThe discovery of MicroR A can be equated with

the idea that weƞve known for years that cars
existed and only recently discovered they have a
transmission.
tƞs that fundamental.ơ
hilip Sharp, h.., obel aureate from M.
.T.
 —
|  
— 
° miR-21 and miR-106a are associated with an
overall poor prognosis and that overexpressions
of miR-181b and miR-203 are associated with
poor outcomes in blacks for colorectal cancer
° MicroR A-31 (miR-31) repressed specific tumor
suppressors and, therefore, may be a novel
pharmacologic target for lung cancer therapy
and chemoprevention.
 —
|  
— 
° igh levels of miR-21 were significantly
correlated with poor response to erceptin.
V— hy  
 
h 
 
 

° iagnosis
° Screening
° ersonalized Medicine
ß ! "— "

 
h 
 
 

° iagnosis
° Screening
° ersonalized Medicine
° revention
 ß  

ÖAt least half of all cancer deaths are preventable

by what we already know about healthy eating,
exercise, maintaining appropriate weight,
avoiding smoking and going for regular
screenings.ơ
Ernest T. awk, M.., M...
Vice resident of the ivision of Cancer revention
and opulation Sciences at The University of
Texas M. . Anderson Cancer Center.
 ß  

° ealthy iving
 ß  

° ealthy iving
° Chemoprevention
ß  

 
 y

5 Clinical Trials
&
11 Systematic Reviews
Are Being Published Every Single Day

Bastian , laszio P, Chalmers
, et al. (2010). Seventy-Five Trials and Eleven Systematic Reviews a Day: ow Will We
Ever Keep Up? PS Med  (9): e1000326. doi:10.131/journal.pmed.1000326.
  W
h

° ew England Journal of Medicine

  W
h

° ew England Journal of Medicine

° Journal of the American Medical Association
  W
h

° ew England Journal of Medicine

° Journal of the American Medical Association
° Cancer
  W
h

° ew England Journal of Medicine

° Journal of the American Medical Association
° Cancer
° Journal of Clinical ncology
  W
h

° Cancer Research
  W
h

° Cancer Research
° Clinical Cancer Research
  W
h

° Cancer Research
° Clinical Cancer Research
° Cancer Epidemiology, Biomarkers & revention
  W
h

° Cancer Research
° Clinical Cancer Research
° Cancer Epidemiology, Biomarkers & revention
° Cancer revention Research
  W
h

° Cancer Research
° Clinical Cancer Research
° Cancer Epidemiology, Biomarkers & revention
° Cancer revention Research
° Molecular Cancer Research
° Molecular Cancer Therapeutics
 #W $  %

° #|& '(#|)
 #W $  %

° #|& '(#|)
ƛ fficially announcing next week
 #W $  %

° #|& '(#|)
ƛ fficially announcing next week
ƛ Editors in Chief, Jose Baselga, M., h.. and ewis
Cantley, h..
 #W $  %

° #|& '(#|)
ƛ fficially announcing next week
ƛ Editors in Chief, Jose Baselga, M.., h.., and ewis
Cantley, h..
ƛ Will be the premier venue for the publication and
broad dissemination of high impact research in all
areas of cancer research
 #W $  %

° #|& '(#|)
ƛ fficially announcing next week
ƛ Editors in Chief, Jose Baselga, M.., h.., and ewis
Cantley, h..
ƛ Will be the premier venue for the publication and
broad dissemination of high-impact research in all
areas of cancer research.
ƛ First papers will be published online April 2011
 #W $  %

° #|& '(#|)
ƛ fficially announcing next week
ƛ Editors in Chief, Jose Baselga, M.., h.., and ewis
Cantley, h..
ƛ Will be the premier venue for the publication and
broad dissemination of high-impact research in all
areas of cancer research
ƛ First papers will be published online April 2011
ƛ
n rint July 2011
 %#'— '$* |

° Conclusions, not titles

 %#'— '$* |

° Conclusions, not titles

° oals
 %#'— '$* |

° Conclusions, not titles

° oals
° opulation Samples
 %#'— '$* |

° Statistics
ƛ  Values, anything less than .05 is significant
 %#'— '$* |

° Statistics
ƛ  Values, anything less than .05 is significant
ƛ azard Ratios
ƛ R=1.23, 95% C
, 1.05-1.10
%#'— '$* |
 $' 'W%##W

° Subscribe to ewswise
° Check Eurekalert
 $' 'W%##W

° Subscribe to ewswise
° Check Eurekalert
° ind a R erson you trust
 J##ß'+%

Jeremy Moore
Senior Manager, Science Communications
ffice: 26-646-055
Cell: 609-519-0212
jeremy.moore@aacr.org
%J
+